A unique subtype within AML is acute promyelocytic leukemia (APL) with PML::RARA, well-known among hematologists for its distinctive morphology, clinical features, and high cure rates with all-trans-retinoic acid (ATRA) combined with arsenic trioxide induction therapy. This evidence concerns the gene PML and acute promyelocytic leukemia.